MyFamily First Technologies
Roche purchased similar capabilities for $200M - Bloodhound. Our ‘Puppy’ has been vetted by a global leader and the first right of refusal has been purchased.
- Stage Full Product Ready
- Industry Healthcare Services
- Location Houston, TX, USA
- Currency USD
- Founded December 2012
- Employees 3
- Website myfamilyfirsttechnologies.com
Company Summary
Rapid evaluation of patients will lower the overall healthcare delivery cost, provide greater independence for age-related diseases, and promotes active lifestyles. In 2013 Roche invested $200M in the Bloodhound prototype for hospital blood diagnostics. MyFamily First Technologies advanced those capabilities, now offering point-of-care testing (POCT) at a disruptively low cost/high margin, nicknamed the Puppy. All from a single finger stick.
Team
-
Glenn Spaulding, M.S., M.D.CEO
The CEO has 30 years experience successfully advancing companies through all stages: from concept to IPO. We have decades in combined successes advancing clinical products through all stages: from idea to production and sales. Our management has launched similar products through fortune 100 companies to global sales.
Advisors
-
tbdLawyerUnconfirmedtbdAccountantUnconfirmed
Previous Investors
-
Clear Lake Medical FoundationUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.